Eisai Inc patents expiration
1. Aricept patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8481565 | EISAI INC | Method for stabilizing anti-dementia drug |
Oct, 2026
(3 years from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2010
Treatment: NA
Dosage: TABLET;ORAL
ARICEPT family patents
2. Banzel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6740669 (Pediatric) | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
May, 2023
(4 months ago) | |
Drugs and Companies using RUFINAMIDE ingredient
Market Authorisation Date: 14 November, 2008
Treatment: NA
Dosage: TABLET;ORAL
BANZEL family patents
3. Dayvigo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 7, 2025 |
| M (M) | Apr 20, 2026 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 2024-04-07
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET;ORAL
DAYVIGO family patents
4. Fycompa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6949571 | EISAI INC | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
Jun, 2024
(8 months from now) | |
| US8772497 | EISAI INC | Method for producing 1, 2-dihydropyridine-2-one compound |
Jul, 2026
(2 years from now) | |
Drugs and Companies using PERAMPANEL ingredient
Market Authorisation Date: 22 October, 2012
Treatment: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; Treatment of partial-onset seizures with or without secondarily...
Dosage: TABLET;ORAL
FYCOMPA family patents
5. Halaven patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6214865 | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jul, 2023
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6214865 (Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(3 months from now) | |
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(3 years from now) | |
|
USRE46965 (Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 28, 2023 |
| M (M) | Sep 13, 2025 |
| Pediatric Exclusivity (PED) | Mar 13, 2026 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
Market Authorisation Date: 15 November, 2010
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
HALAVEN family patents
6. Lenvima patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(2 years from now) | |
| US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(2 years from now) | |
| US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(3 years from now) | |
| US11090386 | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Feb, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 15, 2025 |
| M (M) | Dec 19, 2024 |
| New Indication (I) | Aug 10, 2024 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; Treatment with lenvima by administering lenvima as a suspension
Dosage: CAPSULE;ORAL
LENVIMA family patents
7. Lusedra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6204257 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Jul, 2022
(1 year, 2 months ago) | |
Drugs and Companies using FOSPROPOFOL DISODIUM ingredient
Market Authorisation Date: 12 December, 2008
Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation
Dosage: SOLUTION;INTRAVENOUS
LUSEDRA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic